The University of Chicago Header Logo

Ibrutinib's Cardiotoxicity-An Opportunity for Postmarketing Regulation.

Ibrutinib's Cardiotoxicity-An Opportunity for Postmarketing Regulation. JAMA Oncol. 2021 02 01; 7(2):177-178.

View in: PubMed